Forte Biosciences, Inc.

NasdaqCM:FBRX Stok Raporu

Piyasa değeri: US$1.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Forte Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Forte Biosciences şirketinin kazançlarının yıllık 37.6% oranında düşmesi, yıllık gelirinin ise yıllık 88.9% oranında artması bekleniyor. EPS'nin yıllık 8.2% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-37.6%

Kazanç büyüme oranı

-8.18%

EPS büyüme oranı

Biotechs kazanç büyümesi29.0%
Gelir büyüme oranı88.9%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme27 Jul 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Nov 11

We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Forte Biosciences...
Analiz Makalesi • Apr 19

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Jul 17

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Mar 14

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 24

Large Forte Biosciences shareholder scolds company board of directors

Funicular Funds, which owns 8% of the outstanding shares of Forte Biosciences (NASDAQ:FBRX), excoriated the company's board of directors in a letter over a recent capital raise. In an SEC filing, Funicular said the letter addressed the "Board’s failure to address the legitimate concerns previously raised by stockholders and its decision to embark on a value-destructive, scorched-earth path with a dilutive and unnecessary capital raise, without so much as an explanation for its actions." Funicular is asking to establish a committee of independent directors to investigate shareholder concerns. In July, a pair of large shareholders demanded changes at Forte (FBRX), including a suggestion that the company liquidate.
Analiz Makalesi • Aug 17

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 16

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

FB-401, the lead asset failed in clinical trials. The company has one very early-stage asset they intend to move forward in the clinic, FB-102. Investors are likely to encounter dilution, a high degree of clinical risk and there is insufficient evidence to assess whether FB-401 has any advantages over other therapeutics. Summary Creativity is not my strength so I am reusing the title from an article that I wrote a few months back about Vyne Therapeutics, another dermatology company. The shares of Vyne have fallen 60% since then. The story is at Forte is essentially the same and all too common in biotech. Vyne and Forte both experienced setbacks, institutional investors sold and long term investors have fared poorly. Most importantly, for both companies, there is a suboptimal plan to move forward that exposes investors to a high degree of clinical risk, requires hundreds of millions of capital and has a low chance of rewarding investors in a manner commensurate with this outsized risk. I will outline a few reasons I rate Forte Biosciences (FBRX) a SELL Institutional Investors Major institutional investors have sold and cut their losses. Forte Biosciences had an enviable roster of professional investors including BVF, Orbimed and Perceptive Advisors. These are seasoned investors with a staff of PhD/MDs who are highly capable of assessing the future likelihood of success. All three funds sold their entire stake in the company. This is not always the case after a clinical failure. There are many cases where institutional investors increase their stake at a low price. Three institutional investors selling their entire stake strongly suggests these professionals do not see a bright future. For an unprofitable biotech company, institutional investors are an important source of capital. Funding an unprofitable biotech in the capital markets is very challenging currently. It is not clear Forte will be able to obtain future funding and if they do, terms will likely be unfavorable. What is clear is they have very limited cash ($38.5 m currently) and they will need hundreds of million to develop the new molecule. In fact, they have a shelf registration in place. Investors should expect substantial dilution. The Plan Forward The asset the company intends to move forward after the failure of FB-401 in atopic dermatitis is FB-102. Given this asset is in the very early stages of testing, prudence dictates an assessment as to whether the risk is worth the potential reward. This molecule may enter the clinic for testing as late as 2024. The company's presentation noted development plans in graft versus host disease (GvHD), vitiligo and alopecia areata which represent combined markets of over $6 billion. Each indication will require separate clinical trials to prove safety and efficacy adding substantially to the cost of development. Each of these indications has standard of care treatments. The company notes an unmet medical need. GvHD is a disease where there is a legitimate unmet need but there are other companies much further along in testing including Seres Therapeutics (MCRB) and MaaT Pharma. The unmet need may be satisfied by these entrants and MaaT has already produced favorable safety and efficacy data. Alopecia and vitiligo have very effective treatments currently-JAK inhibitors. The company noted the safety profile of JAK inhibitors. Opzelura is a topical JAK and most Doctors consider the safety profile of the cream to be of no concern whatsoever. In alopecia, where oral JAKS are approved, the safety and efficacy data for all 3 JAK inhibitors (Pfizer, Lilly and Concert) has been favorable but there is a black box warning. From an efficacy standpoint, there is no unmet need. From a safety standpoint, the mechanism of action and side effect profile are related. The JAK inhibitors work in vitiligo and alopecia areata by suppressing the immune system. There is nothing to suggest FB-102 can achieve the suppression of the immune system required for efficacy without the same safety issues. Investors are going to spend hundreds of million dollars developing treatments in indications where there are either treatments approved or assets years ahead of Forte's molecule, FB-102. Investors are taking on a huge amount of risk to enter crowded markets with little assurance of any competitive advantage. Of course, there is also the possibility the molecule does not show efficacy or adequate safety and needs to abandoned leaving Forte with no assets. To make development of FB-102 worthwhile, it would have to offer a benefit over existing treatments. The company presentation does not include the mechanism of action of FB-102 making it impossible to ascertain whether the "proprietary molecule" that involves "antagonism of a pathway for autoimmune disease" has any advantages or is even likely to work. The company cites infrequent dosing as a potential benefit of the treatment. This is an extraordinarily poor reason to spend hundreds of millions to develop a treatment. Dosing is a very unimportant issue in diseases such as GvHD which can be fatal. Vitiligo and alopecia areata are diseases where patients have skin discolorations or baldness and patients are highly motivated to take their medicine.
Seeking Alpha • Jul 07

Forte Biosciences large shareholders make demands for company's future

A pair of large shareholders of Forte Biosciences (NASDAQ:FBRX) are making demands that could impact the company's future, including the suggestion that the company liquidate. In a Wednesday SEC filing, Brad Leonard, managing member of BML Capital Management, which has a 9.1% stake in common shares, wrote that "Forte shareholders would be best served by a complete liquidation as soon as possible." Forte (FBRX) and some shareholders have been at odds over the future of Forte's only asset, FB-102, which is in the preclinical stage for several indications, including alopecia and vitiligo, a conditions that affects skin pigmentation. Leonard noted that since a May announcement on development plans, there has not been a single insider purchase. On Tuesday, Jacob Ma-Weaver, managing member of Funicular Funds, said in a SEC filing that Forte's board had yet to make an "adequate assessment of the potential immediate value creation that could be achieved through a substantial buyback program, tender offer at a premium, or special dividend." Funicular has a 7.5% stake. Seeking Alpha's Quant Rating views Forte (FBRX) as a hold with the only high grade being for valuation.
Analiz Makalesi • Dec 23

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Mar 13

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Analiz Makalesi • Jan 19

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

A look at the shareholders of Forte Biosciences, Inc. ( NASDAQ:FBRX ) can tell us which group is most powerful...
Analiz Makalesi • Nov 25

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:FBRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2028N/A-128N/AN/A2
12/31/2027N/A-107N/AN/A3
12/31/2026N/A-91N/AN/A3
6/30/2026N/A-88-72-72N/A
3/31/2026N/A-76-59-59N/A
12/31/2025N/A-69-51-51N/A
9/30/2025N/A-52-45-44N/A
6/30/2025N/A-42-39-39N/A
3/31/2025N/A-44-35-34N/A
12/31/2024N/A-35-31-31N/A
9/30/2024N/A-34-30-30N/A
6/30/2024N/A-36-31-31N/A
3/31/2024N/A-32-30-30N/A
12/31/2023N/A-31-29-29N/A
9/30/2023N/A-30-23-23N/A
6/30/2023N/A-24-16-16N/A
3/31/2023N/A-18-11-11N/A
12/31/2022N/A-14-8-8N/A
9/30/2022N/A-12-9-9N/A
6/30/2022N/A-17-12-12N/A
3/31/2022N/A-19-15-15N/A
12/31/2021N/A-22-17-17N/A
9/30/2021N/A-23-17-17N/A
6/30/2021N/A-20-20-20N/A
3/31/2021N/A-49-20-20N/A
12/31/2020N/A-46-18-18N/A
9/30/2020N/A-43-15-15N/A
6/30/2020N/A-39-8-8N/A
3/31/2020N/A-5N/A-5N/A
12/31/2019N/A-4N/A-3N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: FBRX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: FBRX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: FBRX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: FBRX gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: FBRX gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: FBRX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/08/26 01:01
Gün Sonu Hisse Fiyatı2026/08/26 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Forte Biosciences, Inc. 10 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Etzer DaroutBarclays
Kalpit PatelB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets